Mittie Doyle is a proven research physician who has held numerous leadership roles in clinical development. She has more than 20 years of experience in the pharmaceutical and biotech industries and academia. Prior to Aro Biotherapeutics, Mittie was vice president, global therapeutic area head, research & development, immunology at CSL Behring. Prior to her time at CSL, she held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals.
During her career, Mittie has led clinical development across a broad range of immune mediated and orphan diseases. She has led teams with responsibilities for design and execution of first-in-human through Phase 2 and 3 trials, resulting in several global regulatory approvals.
Mittie holds a B.A. in romance languages from Princeton University and an M.D. from Yale Medical School. She completed her postdoctoral training at Harvard Medical School, including residency in internal medicine ,at Massachusetts General Hospital and clinical/research fellowship in rheumatology and immunology at Brigham and Women’s Hospital.